Eyeonics

Eyeonics was a pioneering medical technology company focused on the development and commercialization of intraocular lenses for cataract and refractive surgery. The company is most notable for developing the Crystalens, which in 2003 became the first accommodating intraocular lens (IOL) to receive FDA approval. Unlike standard monofocal lenses, the Crystalens technology was designed to mimic the natural focusing ability of the human eye, allowing patients to see clearly across a range of distances. This innovation addressed both cataracts and presbyopia, significantly reducing patient dependence on glasses. In January 2008, Eyeonics was acquired by Bausch & Lomb for approximately $430 million, a move that significantly expanded Bausch & Lomb's presence in the premium IOL market.